Dupixent (dupilumab), an injectable drug from Sanofi and Regeneron Pharmaceuticals Inc. used to treat moderate to severe atopic dermatitis (AD), has been approved by the Food and Drug Administration (FDA).
A drug approved two years ago in the United States to treat schizophrenia is undergoing review in Europe, the final step before doctors there can prescribe it some 5 million patients suffering from the disorder.
Legislation designed to tie U.S. Postal Service retiree health care plans more closely with Medicare could needlessly saddle seniors with two insurance premiums, according to one health policy expert who has studied a bill introduced in the U.S. House of Representatives.
The Food and Drug Administration (FDA) has sent AstraZeneca a complete response letter (CRL) from the regulatory board in response to the development of sodium zirconium cyclosilicate, a drug designed to treat hyperkalaemia.
Change to the country's health care system will be smoother if current fraud and abuse laws are reformed to improve patient outcomes and reduce costs, according to a white paper released by the Healthcare Leadership Council.
The Food and Drug Administration (FDA) has accepted Celgene Corp.'s new drug application for Enasidenib, a treatment for patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation.